Literature DB >> 26179987

Systematic review of the prevalence of Mycobacterium tuberculosis resistance in Saudi Arabia.

Jaffar A Al-Tawfiq1, Kareem Hinedi, Ziad A Memish.   

Abstract

AIM: To quantitatively estimate the prevalence of resistance of Mycobacterium tuberculosis (TB) to first line agents in Saudi Arabia.
METHODS: The overall prevalence of M. tuberculosis resistance was calculated using meta-analysis.
RESULTS: We included 22 studies from Saudi Arabia that were published from 1979 to 2013.A high degree of heterogeneity among studies was observed. Based on random effect methodology, the prevalence (and 95% CI) of the resistance rates were: INH 10.13 (8.13-12.11), rifampicin 5.41 (4.21-6.61), ethambutol 1.29 (1.83-2.37) and streptomycin 6.5 (4.9-8.1), and multi-drug resistant was 6.7 (5.1-8.3).
CONCLUSION: The prevalence of resistance to anti-tuberculous agents was highest for INH followed by streptomycin and rifampicin. Multi-drug resistant tuberculosis remains at 6.7%. The data support the recommendations to use four anti-tuberculous agents as empiric therapy.

Entities:  

Keywords:  Resistance; Saudi Arabia; Systematic review; Tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 26179987     DOI: 10.1179/1973947815Y.0000000058

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  2 in total

1.  Middle East respiratory syndrome coronavirus in the last two years: Health care workers still at risk.

Authors:  Jaffar A Al-Tawfiq; Ziad A Memish
Journal:  Am J Infect Control       Date:  2019-05-23       Impact factor: 2.918

2.  Prevalence and outcome of isoniazid-monoresistant tuberculosis at a university hospital in Saudi Arabia.

Authors:  Khalifa M Binkhamis; Mohammed A Bahatheg; Faisal A Altahan; Saleh S Alwakeel; Khalid A Almutairi; Abdullah F Alsaeed; Dalal A Alkadi; Hanan A Alshafai; Fahad M Almajid; Mazin A Barry
Journal:  Saudi Med J       Date:  2021-06       Impact factor: 1.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.